U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C13H14ClN3O2S
Molecular Weight 311.787
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LY-2033298

SMILES

COC1=C(Cl)C(C)=C2C(SC(C(=O)NC3CC3)=C2N)=N1

InChI

InChIKey=CTEGQKDJTBWFHW-UHFFFAOYSA-N
InChI=1S/C13H14ClN3O2S/c1-5-7-9(15)10(11(18)16-6-3-4-6)20-13(7)17-12(19-2)8(5)14/h6H,3-4,15H2,1-2H3,(H,16,18)

HIDE SMILES / InChI
Molecular Formula C13H14ClN3O2S
Molecular Weight 311.787
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/19940843 | https://www.ncbi.nlm.nih.gov/pubmed/22610522 | https://www.ncbi.nlm.nih.gov/pubmed/24700389

LY2033298 is a selective allosteric modulator for muscarinic acetylcholine M4 receptor. It exerts antipsychotic action in animal models. The compound is able to modulate circadian activity rhythms and morphine-induced conditioned place preference in rats.

CNS Activity

CNS Active
3913
Curator's Comment: LY2033298 is CNS active in animals. No human data available.

Originator

Eli Lilly
237
Curator's Comment: # Eli Lilly

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Positive Allosteric Modulator
179
 7.03 null [pEC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug).
2008 Oct
Impact of species variability and 'probe-dependence' on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor.
2011 Apr
The role of transmembrane domain 3 in the actions of orthosteric, allosteric, and atypical agonists of the M4 muscarinic acetylcholine receptor.
2011 May
Patents

Patents

WO2011044537A2
1
WO2011063415A2
1

Sample Use Guides

In Vivo Use Guide
rats: 10 or 30 mg/kg
Route of Administration: Other
In Vitro Use Guide
0.3-10 uM LY2033298 caused a robust potentiation of the ability of ACh to promote both ERK1/2 phosphorylation and internalization in the NG108-15 cells
Substance Class Chemical
Created
by admin
on Sat Dec 16 08:06:54 GMT 2023
Edited
by admin
on Sat Dec 16 08:06:54 GMT 2023
Record UNII
5YG6JK4ECM
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LY-2033298
Code English
THIENO(2,3-B)PYRIDINE-2-CARBOXAMIDE, 3-AMINO-5-CHLORO-N-CYCLOPROPYL-6-METHOXY-4-METHYL-
Systematic Name English
3-AMINO-5-CHLORO-N-CYCLOPROPYL-6-METHOXY-4-METHYLTHIENO(2,3-B)PYRIDINE-2-CARBOXAMIDE
Systematic Name English
LY2033298
Code English
Code System Code Type Description
CAS
886047-13-8
Created by admin on Sat Dec 16 08:06:54 GMT 2023 , Edited by admin on Sat Dec 16 08:06:54 GMT 2023
PRIMARY
FDA UNII
5YG6JK4ECM
Created by admin on Sat Dec 16 08:06:54 GMT 2023 , Edited by admin on Sat Dec 16 08:06:54 GMT 2023
PRIMARY
PUBCHEM
11536903
Created by admin on Sat Dec 16 08:06:54 GMT 2023 , Edited by admin on Sat Dec 16 08:06:54 GMT 2023
PRIMARY
EPA CompTox
DTXSID10468233
Created by admin on Sat Dec 16 08:06:54 GMT 2023 , Edited by admin on Sat Dec 16 08:06:54 GMT 2023
PRIMARY
Related Record Type Details
Structure of LY-2033298
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966